A Review of Afamin A Metabolic Novel Marker of Many Diseases
DOI:
https://doi.org/10.31185/wjps.250Keywords:
Afamin, Type 2 diabetes mellitus ,obesity.Abstract
Human plasma vitamin E-binding glycoprotein afamin is mostly produced in the liver and released into the circulation. The review in this study related to a glycoprotein afamin marker that is important in many disease(Type 2 diabetes mellitus,cancer,obesity , Gestational diabetes mellitus,oxidative stress,and metabolic syndrome. Although ovarian follicles and human cerebrospinal fluid also contain sizable amounts of AFM, the liver is the main organ that generates it. Though there are minor AFM manifestations have been also reported in the human heart, testis, brain, kidney, and ovary. Afamin is promising metabolic novel marker for gestational diabetes,type 2 diabetes mellitus cancer,metabolic syndrome,and related disease.
References
F. Kronenberg et al., “Plasma concentrations of afamin are associated with the prevalence and development of metabolic syndrome,” Circ. Cardiovasc. Genet., vol. 7, no. 6, pp. 822–829, 2014.
B. Dieplinger and T. Mueller, “Afamin an emerging marker for type 2 diabetes mellitus,” J. Lab. Precis. Med., vol. 3, no. 1, 2018.
B. Kollerits et al., “Plasma concentrations of afamin are associated with prevalent and incident type 2 diabetes: a pooled analysis in more than 20,000 individuals,” Diabetes Care, vol. 40, no. 10, pp. 1386–1393, 2017.
A. Prystupa et al., “Afamin and adropin in patients with alcohol-induced liver cirrhosis,” Ann. Agric. Environ. Med., vol. 25, no. 3, pp. 527–531, 2018.
B. Dieplinger et al., “Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma,” Clin. Chim. acta, vol. 425, pp. 236–241, 2013.
G. J. Kashtl, B. A. Abed, L. O. Farhan, I. Noori, and A. S. D. Salman, “A Comparative Study to Determine LDH Enzyme Levels in Serum Samples of Women with Breast Cancer and Women with Breast Cancer and Type 2 Diabetes Mellitus,” 2023.
S. Chen et al., “Association between serum afamin levels with nonalcoholic associated fatty liver disease,” Can. J. Gastroenterol. Hepatol., vol. 2022, 2022.
L. O. Farhan, B. A. Abed, and I. N. Salman, “Insulin Like Growth Factor Binding Protein 7 as a Novel Diagnostic Marker in Sera of Iraqi Patients with Acromegaly,” Baghdad Sci. J., vol. 20, no. 3 (Suppl.), p. 979, 2023.
L. O. Farhan, B. A. Abed, and A. Dawood, “Comparison Study between Adipsin Levels in Sera of Iraqi Patients with Diabetes and Neuropathy,” Baghdad Sci. J., vol. 20, no. 3, p. 726, 2023.
H. Dieplinger and B. Dieplinger, “Afamin—A pleiotropic glycoprotein involved in various disease states,” Clin. Chim. Acta, vol. 446, pp. 105–110, 2015.
R. Bouillon, F. Schuit, L. Antonio, and F. Rastinejad, “Vitamin D binding protein: a historic overview,” Front. Endocrinol. (Lausanne)., vol. 10, p. 910, 2020.
H. S. Lichenstein et al., “Afamin is a new member of the albumin, alpha-fetoprotein, and vitamin D-binding protein gene family.,” J. Biol. Chem., vol. 269, no. 27, pp. 18149–18154, 1994.
V. Mishra and R. J. Heath, “Structural and biochemical features of human serum albumin essential for eukaryotic cell culture,” Int. J. Mol. Sci., vol. 22, no. 16, p. 8411, 2021.
B.-J. Kim et al., “Afamin secreted from nonresorbing osteoclasts acts as a chemokine for preosteoblasts via the Akt-signaling pathway,” Bone, vol. 51, no. 3, pp. 431–440, 2012.
I. Kratzer et al., “Afamin is synthesized by cerebrovascular endothelial cells and mediates α‐tocopherol transport across an in vitro model of the blood–brain barrier,” J. Neurochem., vol. 108, no. 3, pp. 707–718, 2009.
S. N. Ahmed and R. J. Ali, “Association of Afamin Concentration with Type 1 and Type 2 Diabetes Mellitus,” Zanco J. Pure Appl. Sci., vol. 33, no. 5, 2021.
T. Kurdiova et al., “Serum afamin a novel marker of increased hepatic lipid content,” Front. Endocrinol. (Lausanne)., vol. 12, p. 670425, 2021.
B. Klop, J. W. F. Elte, and M. Castro Cabezas, “Dyslipidemia in obesity: mechanisms and potential targets,” Nutrients, vol. 5, no. 4, pp. 1218–1240, 2013.
E. Björnson, M. Adiels, M.-R. Taskinen, and J. Borén, “Kinetics of plasma triglycerides in abdominal obesity,” Curr. Opin. Lipidol., vol. 28, no. 1, pp. 11–18, 2017.
E. Wieczorek, A. Ćwiklińska, A. Kuchta, B. Kortas-Stempak, A. Gliwińska, and M. Jankowski, “The differential effects of HDL subpopulations on lipoprotein lipase (LPL)-mediated VLDL catabolism,” Biomedicines, vol. 9, no. 12, p. 1839, 2021.
P. Marchio, S. Guerra-Ojeda, J. M. Vila, M. Aldasoro, V. M. Victor, and M. D. Mauricio, “Targeting early atherosclerosis: a focus on oxidative stress and inflammation,” Oxid. Med. Cell. Longev., vol. 2019, 2019.
L. O. Farhan, F. M. Khaleel, and E. M. Taha, “Human β-Defensin 2 as a Novel Diagnostic Marker of Iraqi Patients with Rheumatoid Arthritis,” Iraqi J. Sci., pp. 2135–2143, 2023.
B. Vergès, “Pathophysiology of diabetic dyslipidaemia: where are we?,” Diabetologia, vol. 58, no. 5, pp. 886–899, 2015.
R. J. Abd Al-Ghanny, M. M. B. Al-Moosawi, and B. A. Abd, “Effects of Vitamin D Deficiency in Polycystic Ovarian Syndrome,” Iraqi J. Sci., pp. 33–42, 2022.
C. Brockes, C. Buchli, R. Locher, J. Koch, and W. Vetter, “Vitamin E prevents extensive lipid peroxidation in patients with hypertension,” Br. J. Biomed. Sci., vol. 60, no. 1, pp. 5–8, 2003.
P. M. Catalano, L. Huston, S. B. Amini, and S. C. Kalhan, “Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus,” Am. J. Obstet. Gynecol., vol. 180, no. 4, pp. 903–916, 1999.
N. U. G. Mohammed, F. M. Khaleel, and F. I. Gorial, “Cystatin D as a new diagnostic marker in rheumatoid arthritis,” Gene Reports, vol. 23, p. 101027, 2021.
G. K. Jakubiak et al., “‘Obesity and insulin resistance’ is the component of the metabolic syndrome most strongly associated with oxidative stress,” Antioxidants, vol. 11, no. 1, p. 79, 2021.
S. Thériault, Y. Giguère, J. Massé, J. Girouard, and J.-C. Forest, “Early prediction of gestational diabetes: a practical model combining clinical and biochemical markers,” Clin. Chem. Lab. Med., vol. 54, no. 3, pp. 509–518, 2016.
F. González, N. S. Rote, J. Minium, and J. P. Kirwan, “Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome,” J. Clin. Endocrinol. Metab., vol. 91, no. 1, pp. 336–340, 2006.
N. U. G. Mohammed, F. M. Khaleel, and F. I. Gorial, “The Role of Serum Chitinase-3-Like 1 Protein (YKL-40) Level and its Correlation with Proinflammatory Cytokine in Patients with Rheumatoid Arthritis,” Baghdad Sci. J., 2022.
H. Yamashita, J. Shao, and J. E. Friedman, “Physiologic and molecular alterations in carbohydrate metabolism during pregnancy and gestational diabetes mellitus,” Clin. Obstet. Gynecol., vol. 43, no. 1, pp. 87–98, 2000.
J. P. Kirwan et al., “TNF-α is a predictor of insulin resistance in human pregnancy,” Diabetes, vol. 51, no. 7, pp. 2207–2213, 2002.
F. Gonzalez, C. L. Sia, M. K. Shepard, N. S. Rote, and J. Minium, “Inflammation in response to glucose ingestion is independent of excess abdominal adiposity in normal-weight women with polycystic ovary syndrome,” J. Clin. Endocrinol. Metab., vol. 97, no. 11, pp. 4071–4079, 2012.
M. Hubalek et al., “The vitamin E-binding protein afamin increases in maternal serum during pregnancy,” Clin. Chim. acta, vol. 434, pp. 41–47, 2014.
A. O. Almobarak et al., “The prevalence of diabetes and metabolic syndrome and associated risk factors in Sudanese individuals with gallstones: a cross sectional survey,” Transl. Gastroenterol. Hepatol., vol. 5, 2020.
N.-Y. Ko, Y.-T. C. Lo, P.-C. Huang, Y.-C. Huang, J.-L. Chang, and H.-B. Huang, “Changes in insulin resistance mediate the associations between phthalate exposure and metabolic syndrome,” Environ. Res., vol. 175, pp. 434–441, 2019.
L. Fontana, J. C. Eagon, M. E. Trujillo, P. E. Scherer, and S. Klein, “Visceral fat adipokine secretion is associated with systemic inflammation in obese humans,” Diabetes, vol. 56, no. 4, pp. 1010–1013, 2007.
N. De Rekeneire et al., “Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study,” Diabetes Care, vol. 29, no. 8, pp. 1902–1908, 2006.
J. M. Humphries et al., “Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer,” Biochim. Biophys. Acta (BBA)-Proteins Proteomics, vol. 1844, no. 5, pp. 1051–1058, 2014.
A. Köninger et al., “Is Afamin a novel biomarker for gestational diabetes mellitus? A pilot study,” Reprod. Biol. Endocrinol., vol. 16, pp. 1–11, 2018.
S. A. Erol et al., “Evaluation of maternal serum afamin and vitamin E levels in pregnant women with COVID‐19 and its association with composite adverse perinatal outcomes,” J. Med. Virol., vol. 93, no. 4, pp. 2350–2358, 2021.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 layla
This work is licensed under a Creative Commons Attribution 4.0 International License.
